Sanofi, tolebrutinib
The totality of data from Sanofi clinical trials indicates that Tolebrutinib may target inflammation thought to contribute to ...
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
B.Riley Financial analyst William Wood has reiterated their bullish stance on IMUX stock, giving a Buy rating on September 16. William Wood ...
Sanofi's chief executive, Paul Hudson, said in an interview on Monday that the company is poised for strong growth from a ...
The FDA approved Sanofi's Sarclisa (isatuximab) in combination with VRd as a first-line treatment for newly diagnosed ...
The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.